Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Alexander Egeberg, MD, PhD, DMSc
University of Copenhagen and Bispebjerg Hospital
Copenhagen, Denmark
BioPUBLICATIONS
Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): An International, Multicentre, Randomised, Placebo-controlled Trial. Morita A, Strober B, Burden AD, et al. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. PMID: 37738999.
Why this article was chosen
Generalized pustular psoriasis (GPP) is a disease with limited effective treatment options. Regulatory authorities, including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), have approved intravenously delivered spesolimab for the treatment of acute flares of GPP. Recently, a 48-week study examined the efficacy and safety of subcutaneous delivery of spesolimab to prevent GPP flares. The results support using spesolimab for long-term treatment in patients with GPP.
Commentary
Recent decades have seen extraordinary advances and approvals of new therapies for plaque psoriasis, with specific IL-17 and IL-23 inhibitors, biosimilars, and, most recently, novel oral therapies such as TYK-2 inhibitors becoming available.
Nevertheless, patients with other psoriasis subtypes, particularly pustular forms, face more significant treatment challenges, and therapeutic options in these cases remain limited. GPP is a rare and potentially life-threatening condition characterized by the rapid development of sterile pustules on the skin and often accompanied by systemic symptoms. Flares of GPP are unpredictable and have historically necessitated hospitalization for extended periods, with a significant mortality rate of up to 7% during hospitalization or within a year post-discharge.1
However, recent advancements in GPP treatment include the approval of IL-23 inhibitors in select Asian countries and the development of targeted biologics such as spesolimab and imsidolimab specifically for GPP.2 These drugs involve direct inhibition of the IL-36 receptor, which is of particular interest since dysregulation of the IL-36 pathway occurs in many, but not all, GPP cases.3, 4
The EMA and FDA approvals of intravenous spesolimab for GPP flares marked a significant advancement in the treatment landscape for GPP. Clinical trials and emerging research have shown promising results, demonstrating safety and efficacy in managing this challenging condition. However, since few dermatologists provide intravenous infusions in their clinics, this may limit its use in specialized clinics and in-patient settings.
The present study assessed several doses of subcutaneous spesolimab prevention of GPP flares.5 Over the course of 48 weeks, significantly fewer patients treated subcutaneously with high-dose spesolimab (600 mg loading dose followed by 300 mg every four weeks) developed GPP flares (n=3 [10%]) compared with the placebo group (n=16 [52%]). The study also noted an absence of flares from week 4 through week 48 in the high-dose group, albeit with a higher incidence of serious adverse events compared to placebo (10% vs. 3%).
This study is valuable considering the underserved GPP patient population. A subcutaneous formulation of spesolimab could offer a more convenient treatment approach, and the study underscores the importance of a proactive treatment approach to prevent flares.
Nonetheless, the balance between treatment efficacy and safety remains crucial, particularly considering the multiple comorbidities seen in GPP patients.1 Moreover, while promising for GPP, trials have revealed spesolimab’s inefficacy for other psoriasis subtypes, such as palmoplantar pustulosis (PPP), leaving this variant with substantial unmet medical needs.6 Thus, while these findings are promising for a subset of psoriasis patients, there is still much to be done for our patients with pustular forms of psoriasis.
References
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.
Medical Adherence for Orals Systemics, Biologics, and Phototherapy in the Context of Psoriasis Patients
Learn the dynamics of psoriasis treatments, emphasizing patient adherence challenges. From evolving therapies to oral and biologic agents, understand real-world data and adherence patterns. Gain insights into long-term disease management and the crucial role of adherence in optimizing patient outcomes.
World Psoriasis Day 2023: Empowering Access to Timely Treatment and Universal Healthcare from Psoriasis Advocates Worldwide
IPC stands for accessible treatment and universal healthcare on World Psoriasis Day and beyond. Gain insights from experts on the significance of timely care. Join the conversation and share your voice on psoriasis care.
Subscribe to the IPC Newsletter